Influenza Vaccine Information*
Manufacturer / Trade Name / How Supplied / Age Group / Route / VaccineCSL Limited / Afluria / 0.5 mL (single-dose syringe) / 9 years & older** / IM / IIV3
5.0 mL (multi-dose vial)
GlaxoSmithKline / Fluarix / 0.5 mL (single-dose syringe) / ≥ 36 mos / IM / IIV3
FluarixQuadrivalent / 0.5 mL (single-dose syringe) / IM / IIV4
ID Biomedical Corp of Quebec, a subsidiary of GlaxoSmithKline / FluLaval / 5.0 mL (multi-dose vial) / ≥36 mos / IM / IIV3
FluLavalQuadrivalent / 5.0 mL (multi-dose vial) / IM / IIV4
Protein Sciences Corporation / Flublok (no eggproteins, antibiotics, or preservatives) / 0.5 mL (single-dose vial) / 18 - 49 years / IM / Recombinant
Medimmune / FluMistQuadrivalent / 0.2 mL (single-use nasal spray) / 2 - 49 years / IN / LAIV, Quadrivalent
Novartis Vaccines / Fluvirin / 0.5 mL (single-dose syringe) / ≥4 years / IM / IIV3
5.0 mL (multi-dose vial)
Flucelvax / 0.5 mL (single-dose syringe) / ≥18 / IM / IIV3
Sanofi Pasteur / Fluzone / 0.25 mL (single-dose syringe) / 6 - 35 mos / IM / IIV3
0.5 mL (single-dose syringe) / ≥ 36 mos
0.5 mL (single-dose vial) / ≥ 36 mos
5.0 mL (multi-dose vial) / 6 – 35 mos
Fluzone High-Dose / 0.5 mL (single-dose syringe) / ≥ 65 years / IM / IIV3 High Dose
Fluzone Intradermal / 0.1 mL (single-dose microinjection system) / 18 - 64 years / ID / IIV3
FluzoneQuadrivalent / 0.25 mL (single-dose syringe); / 6 - 35 months / IIV4
0.5 mL(single-dose syringe) / ≥ 36 months
0.5 mg (single-dose vial) / ≥ 36 months
5.0 mL (multi-dose vial) / ≥ 6 months
Abbreviations: ID = intradermal; IM = intramuscular; IN = intranasal; LAIV = live-attenuated influenza vaccine; IIV4 = quadrivalent inactivated vaccine;IIV3 = trivalent inactivated vaccine
* Vaccination providers should consult Food and Drug Administration–approved prescribing information for influenza vaccines for the most updated information, including indications, contraindications, and precautions
**Age indication per package insert is ≥5 years; however, the Advisory Committee on Immunization Practices recommends that Afluria not be used in children aged 6 months through 8 years because of increased risk for febrile reactions noted in this age group with CSL's 2010 Southern Hemisphere TIV. If no other age-appropriate, licensed inactivated seasonal influenza vaccine is available for a child aged 5 through 8 years who has a medical condition that increases the child's risk for influenza complications, Afluria can be used; however, vaccination providers should discuss with the parents or caregivers the benefits and risks of influenza vaccination with Afluria before administering this vaccine. Afluria may be used in persons aged ≥9 years.
Resources:
Influenza Vaccine Products for the 2013-2014 Influenza Season.Immunization Action Coalition. Sep 2013.
Influenza Vaccine Information, by age group --- United States, 2014—15 influenza season. Center for Disease Control and Prevention. Page last updated October 29, 2012.
Consulted manufacturer package inserts for each vaccine product.
Last updated August 18, 2014